Lars Lannfelt & BioArctic
3 shared events · Importance 3 · Last updated May 28, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Lars Lannfelt: Lars Lannfelt was re-elected as an ordinary board member of BioArctic.
BioArctic: BioArctic held its Annual General Meeting, making several key resolutions including dividend payment, board re-elections, and approval of an incentive program, which directly impacts its corporate governance and shareholder value.
May 28, 2026 · 9 articles
Business
Lars Lannfelt: Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease formed the basis for the development of Lecanemab by BioArctic.
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Lars Lannfelt and BioArctic interact across events, view sentiment trends, and discover connected entities.
Open Dashboard